WO2001046035A1 - Container with two compartments and a mixing device - Google Patents
Container with two compartments and a mixing device Download PDFInfo
- Publication number
- WO2001046035A1 WO2001046035A1 PCT/US2000/033925 US0033925W WO0146035A1 WO 2001046035 A1 WO2001046035 A1 WO 2001046035A1 US 0033925 W US0033925 W US 0033925W WO 0146035 A1 WO0146035 A1 WO 0146035A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- upper container
- container
- cap
- tubular sleeve
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D51/00—Closures not otherwise provided for
- B65D51/24—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes
- B65D51/28—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials
- B65D51/2807—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container
- B65D51/2814—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it
- B65D51/2842—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being provided with a preformed weakened line
- B65D51/285—Closures not otherwise provided for combined or co-operating with auxiliary devices for non-closing purposes with auxiliary containers for additional articles or materials the closure presenting means for placing the additional articles or materials in contact with the main contents by acting on a part of the closure without removing the closure, e.g. by pushing down, pulling up, rotating or turning a part of the closure, or upon initial opening of the container the additional article or materials being released by piercing, cutting or tearing an element enclosing it said element being provided with a preformed weakened line ruptured by a sharp element, e.g. a cutter or a piercer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D47/00—Closures with filling and discharging, or with discharging, devices
- B65D47/04—Closures with discharging devices other than pumps
- B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
- B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
Definitions
- the present invention generally pertains to the delivery of unstable liquids. More particularly, but not by way of limitation, the present invention pertains to the delivery of unstable pharmaceutical preparations to the eye.
- Topical pharmaceutical preparations for the eye are typically formulated as a liquid solution or suspension.
- certain topical preparations have individual components that, if mixed, have a shelf life of only a few weeks.
- one of the components is in a powdered form, and the other component is in a liquid form.
- Such topical pharmaceutical preparations were initially packaged with the unstable components in two separate containers. The components were then dispensed in certain specified
- One aspect of the present invention is a device for the delivery of a pharmaceutical preparation to the eye having a first component and a second component.
- the device includes an upper container for receiving the first component and having a bottom.
- the first component includes an unstable anti-cataract agent.
- the device also includes a lower container for receiving a second component.
- the second component includes a liquid carrier for the first component.
- the device further includes a tubular sleeve movably disposed within the upper container and a cap rotationally coupled to the upper container. When the cap is screwed onto the upper container, the tubular sleeve tears the bottom of the upper container to place the first component in communication with the second component.
- FIG. 1 is an exploded view of a device for the delivery of unstable pharmaceutical preparations according to a preferred embodiment of the present invention
- FIG. 2 is a cross-sectional view of FIG. 1
- FIG. 3 is a front view of the device of FIG. 1 in the assembled state in which the unstable components of the pharmaceutical preparation are not mixed;
- FIG. 4 is a cross-sectional view of FIG. 3;
- FIG. 5 is an enlarged, cross-sectional view of the upper container of the device of FIG. 1 ;
- FIG. 6 is a sectional view of FIG. 5 taken along line 6-6;
- FIG. 7 is a top view of the safety ring of the device of FIG 1 ;
- FIG. 8 is an exploded, cross-sectional, fragmentary view of the tubular sleeve, upper container, and cap of the device of FIG. 1 ;
- FIG. 9 is a front view of the device of FIG. 1 in the assembled state in which the unstable components of the pharmaceutical preparation have been mixed, the cap is removed, and the device is ready to dispense the mixed pharmaceutical preparation;
- FIG. 10 is a cross-sectional, fragmentary view of FIG. 9.
- FIGS. 1-10 of the drawings like numerals being used for like and corresponding parts of the various drawings.
- Device 10 for the delivery of unstable liquids is shown according to a preferred embodiment of the present invention.
- Device 10 is
- device 10 is described hereinafter as a device for
- device 10 generally includes a
- tubular sleeve 16 is coupled to lower container 12
- tubular sleeve 16 is disposed within and coupled to upper container 14
- cap 18 covers tubular sleeve 16 and is removably
- lower container 12 is formed of low density polyethylene
- upper container 14 is formed of high density polyethylene
- tubular sleeve 16 is formed of Zylar
- a copolymer available from NOVA Chemicals of Leominster, Massachusetts and cap 18 is formed of polypropylene.
- Upper container 14 has a reservoir 20 for holding a first component 22 of a pharmaceutical preparation.
- Lower container 12 has a reservoir 24 for holding a second component 26 of a pharmaceutical
- first component 22 is unstable in second component 26 after a certain time period, which may be as long as several weeks or months, or as short as a few
- Lower container 12 includes a hollow neck 28 that includes two ring shaped edges 30 and 32. Stria 34 are located on edges 30 and 32. A shoulder 36 is located at the junction of neck 28 and reservoir 24. Sealing rings 37 are located on the internal surface
- upper container 14 includes a surface 82 that mates with sealing rings 37 of lower container 12 to prevent leakage of second component 26 from reservoir 24 or entry of air into reservoir 24.
- Upper container 14 also includes a
- flap 38 that surrounds neck 28 of lower container 12. As shown best in FIG. 5, flap 38 includes two ring shaped ribs 40 and 42 disposed on the internal surface 44 of flap 38 and
- Stria 46 run vertically along internal surface 44 from rib 40 to the internal surface of shoulder 48. Although not shown in the FIGS., stria 46 also run horizontally and radially along the internal surface of shoulder 48 toward the longitudinal axis of upper container 14. When upper container 14 is disposed on lower container 12, stria 34 of edges 30 and 32 couple with stria 46 to
- a plurality of sawteeth 50 are disposed on the external surface of shoulder 48. As shown in FIG. 7, sawteeth 50 mate with flexible wings 52 to removably couple safety seal 19 to upper container 14.
- Safety seal 19 has a ring-shaped geometry with a perforation at connecting point 58.
- Safety seal 19 has an axial wing 56
- Upper container 14 also has a neck 55 having external threads 56 for mating with internal threads 60 of cap 18, as is best shown in FIG. 8.
- upper container 14 has bottom 62 that is tearable along a perforated line 64 disposed about the periphery of bottom 62.
- Tubular sleeve 16 includes a hollow body 64 having a truncated cone-shaped portion 66 on one end and a helicoidal edge 68 on an opposite end. Truncated cone- shaped portion 66 has a internal channel 70 terminating in a reverse truncated cone- shaped hole 72 that serves as the nozzle or dropper to dispense a pharmaceutical
- truncated cone-shaped portion 66 may be modified to include a conventional "Luer Lok” that complies with Luer Taper Specification 70.1 of the American Standards Association and that allows coupling to a
- Helicoidal edge 68 preferably has a small horizontal section 74.
- Tubular sleeve 16 also includes a first sealing ring 76 and a second sealing ring 78 disposed on the external surface of body 64.
- Sealing rings 76 and 78 mate with internal surface 84 of reservoir 20 of upper container
- cap 18 preferably has a member 80 that seals hole 72 when cap 18 is screwed onto upper container 14.
- reservoir 20 of upper container 14 holds first component 22 of a pharmaceutical preparation.
- Reservoir 24 of lower container 12 holds a second component 26 of a pharmaceutical preparation.
- second component 26 may be the unstable components of a liquid other than a pharmaceutical preparation.
- First component 22 preferably comprises an ophthalmically effective amount of one or more pharmaceutically active agents.
- First component 22 may also comprise an ophthalmically acceptable carrier.
- ophthalmically acceptable carrier refers to any substance or combination of substances that are non-reactive with the pharmaceutically active agent and suitable for administration to a user's eye. Solubilizers and stabilizers are deemed to be non-reactive. By way of example, an ophthalmically acceptable carrier.
- acceptable carrier may comprise any combination of preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, solubilizers, stabilizers, pH adjusters, tonicity agents, fillers, and water.
- Preferred pharmaceutically active agents are agents for the prevention and/or treatment of cataracts.
- Preferred anti-cataract agents are agents for the prevention and/or treatment of cataracts.
- First component 22 may be in a powder
- Second component 26 preferably comprises an ophthalmically effective amount of
- Second component 26 may also comprise an ophthalmically acceptable carrier. Second component 26 preferably utilizes the same preferred pharmaceutically active agents as first component 22. Alternatively, second
- component 26 may comprise an ophthalmically acceptable carrier but no pharmaceutically active agent.
- second component 26 acts as a diluent to first component 22.
- first component 22 may comprise an ophthalmically acceptable carrier but no pharmaceutically active agent, and second component 26 may comprise one or more pharmaceutically active agents.
- first component 22 acts as a diluent for second component 26.
- Device 10 is assembled using conventional techniques.
- Device 10 is preferably sterilized by conventional gamma radiation methods if such methods do not inhibit the efficacy of the pharmaceutical preparation.
- device 10 may be sterilized by conventional Eto methods, if necessary.
- device 10 is in a first position in which components 22 and 26 are unmixed.
- a user first moves axial wing 56 of safety seal 19 radially outward, breaking connecting point 59.
- the user then holds axial wing 56 and rotates safety seal 19 about a longitudinal axis of device 10, causing sawteeth 50 of upper container 14 to engage flexible wings 52 of safety seal 19.
- Such rotation splits safety seal 19 at connection point 58.
- the user can then remove safety seal 19 from device 10.
- First component 22 is then in communication with second component 26, and may be further mixed by shaking device 10, if necessary.
- sealing rings 76 and 78 mate with internal surface 84 of upper container 14 to prevent leakage of the components from reservoirs 20 and 24 or entry of air into the reservoirs.
- the mixed pharmaceutical preparation may be dispensed into the eye of a user by squeezing on the external surface of lower container 12 so as to force the mixture through nozzle 66 of tubular sleeve 16.
- member 80 seals hole 72.
- EXAMPLE Device 10 may be used to deliver an ophthalmic pharmaceutical preparation comprising a first component 22 that is a powder having sodium pirenoxine as a pharmaceutically active agent and a second component 26 that acts as a ophthalmically acceptable carrier for first component 22.
- First component 22 preferably has a weight of
- First component 22 contains 0.714 % weight/weight sodium pirenoxine, 16.00 % weight/weight boric acid,
- Second component 26 preferably has a volume of
- second component 26 is 1.2 % weight/volume boric acid, 0.0095 % weight/volume sodium tetraborate 10 H 2 O, 0.16 % weight/volume potassium chloride, 0.02 % weight/volume nipagin M, 0.01 % weight/volume nipasol M, 0.1 % weight/volume thiomersal (0.1 % weight/volume solution), and a quantity of purified water sufficient to adjust the volume of second component 26 to 100%.
- first component 22 and second component 26 exhibit good stability results for up to twenty-four months.
- an effective anti-cataract pharmaceutical preparation may be delivered
- the present invention is illustrated herein by example, and various modifications may be made by a person of ordinary skill in the art.
- the geometries of the device and its individual components may be modified from the geometries described for the preferred embodiments.
- the device may be used with unstable ophthalmic pharmaceutically active agents other than anti-cataract agents, or with other
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Mechanical Engineering (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
A device (10) for the delivery of unstable ophthalmic pharmaceutical preparations is disclosed. The device includes an upper container (14) for receiving a first component of the preparation and a lower container (12) for receiving a second component of the preparation. The first and second components are unstable when mixed. Advantageous preparations for use in the device are also disclosed.
Description
CONTAINER WITH TWO COMPARTMENTS AND A MIXING DEVICE
This application claims the priority of U.S. Provisional Application No. 60/172,657, filed, December 20, 1999.
Field of the Invention
The present invention generally pertains to the delivery of unstable liquids. More particularly, but not by way of limitation, the present invention pertains to the delivery of unstable pharmaceutical preparations to the eye.
Description of the Related Art
Topical pharmaceutical preparations for the eye are typically formulated as a liquid solution or suspension. However, certain topical preparations have individual components that, if mixed, have a shelf life of only a few weeks. Typically, one of the components is in a powdered form, and the other component is in a liquid form. Such topical pharmaceutical preparations were initially packaged with the unstable components in two separate containers. The components were then dispensed in certain specified
amounts from their separate containers into a third container and mixed just prior to deliver)'. Delivery of the mixed preparation was typically accomplished via a conventional dropper. Because of the inconvenience of and the risk of user non- compliance with such two container preparations, various containers were developed having two. separate compartments for the unstable components. Such containers could be manipulated by a user to mix the components just prior to delivery and then deliver the mixed preparation via an integrated nozzle. U.S. Patent Nos. 5.474,209 and 5.782.345.
which are incorporated herein in their entirety by this reference, provide examples of such containers.
However, a need still exists in the pharmaceutical industry for an effective means of delivering unstable pharmaceutical preparations to the eye. The present invention provides advantageous devices and formulations to meet this need.
Summary of the Invention
One aspect of the present invention is a device for the delivery of a pharmaceutical preparation to the eye having a first component and a second component. The device includes an upper container for receiving the first component and having a bottom. The first component includes an unstable anti-cataract agent. The device also includes a lower container for receiving a second component. The second component includes a liquid carrier for the first component. The device further includes a tubular sleeve movably disposed within the upper container and a cap rotationally coupled to the upper container. When the cap is screwed onto the upper container, the tubular sleeve tears the bottom of the upper container to place the first component in communication with the second component.
Brief Description of the Drawings For a more complete understanding of the present invention, and for further
objects and advantages thereof, reference is made to the following description taken in conjunction with the accompanying drawings in which:
FIG. 1 is an exploded view of a device for the delivery of unstable pharmaceutical preparations according to a preferred embodiment of the present invention; FIG. 2 is a cross-sectional view of FIG. 1;
FIG. 3 is a front view of the device of FIG. 1 in the assembled state in which the unstable components of the pharmaceutical preparation are not mixed;
FIG. 4 is a cross-sectional view of FIG. 3;
FIG. 5 is an enlarged, cross-sectional view of the upper container of the device of FIG. 1 ;
FIG. 6 is a sectional view of FIG. 5 taken along line 6-6;
FIG. 7 is a top view of the safety ring of the device of FIG 1 ;
FIG. 8 is an exploded, cross-sectional, fragmentary view of the tubular sleeve, upper container, and cap of the device of FIG. 1 ;
FIG. 9 is a front view of the device of FIG. 1 in the assembled state in which the unstable components of the pharmaceutical preparation have been mixed, the cap is removed, and the device is ready to dispense the mixed pharmaceutical preparation; and
FIG. 10 is a cross-sectional, fragmentary view of FIG. 9.
Detailed Description of Preferred Embodiments
The preferred embodiments of the present invention and their advantages are best understood by referring to FIGS. 1-10 of the drawings, like numerals being used for like and corresponding parts of the various drawings.
Referring generally to FIGS. 1-8, a device 10 for the delivery of unstable liquids is shown according to a preferred embodiment of the present invention. Device 10 is
preferably used to deliver topical pharmaceutical preparations to the eye. For ease of description but not by way of limitation, device 10 is described hereinafter as a device for
the delivery of topical pharmaceutical preparations to the eye.
As shown best in the exploded views of FIGS. 1-2, device 10 generally includes a
lower container 12, and upper container 14, a tubular sleeve or member 16, a cap 18. and
a safety seal 19. As shown best in FIGS. 3 and 4, in the assembled state of device 10, upper container 14 is coupled to lower container 12, tubular sleeve 16 is disposed within and coupled to upper container 14, cap 18 covers tubular sleeve 16 and is removably
coupled to upper container 14, and safety seal 19 is disposed around upper container 14 below cap 18. Cap 18 and safety seal 19 are shown in dashed lines in FIG. 4 for clarity of illustration. The various portions of device 10 are preferably formed from conventional polymeric materials. Most preferably, lower container 12 is formed of low density polyethylene, upper container 14 is formed of high density polyethylene, tubular sleeve 16 is formed of Zylar, a copolymer available from NOVA Chemicals of Leominster, Massachusetts, and cap 18 is formed of polypropylene. Upper container 14 has a reservoir 20 for holding a first component 22 of a pharmaceutical preparation. Lower container 12 has a reservoir 24 for holding a second component 26 of a pharmaceutical
preparation. When mixed, first component 22 is unstable in second component 26 after a certain time period, which may be as long as several weeks or months, or as short as a few
hours or minutes.
Lower container 12 includes a hollow neck 28 that includes two ring shaped edges 30 and 32. Stria 34 are located on edges 30 and 32. A shoulder 36 is located at the junction of neck 28 and reservoir 24. Sealing rings 37 are located on the internal surface
of neck 28 above shoulder 36. As shown best in FIGS. 2 and 4, upper container 14 includes a surface 82 that mates with sealing rings 37 of lower container 12 to prevent leakage of second component 26 from reservoir 24 or entry of air into reservoir 24. Upper container 14 also includes a
flap 38 that surrounds neck 28 of lower container 12. As shown best in FIG. 5, flap 38 includes two ring shaped ribs 40 and 42 disposed on the internal surface 44 of flap 38 and
for mating with edges 30 and 32 of lower container 12. Stria 46 run vertically along
internal surface 44 from rib 40 to the internal surface of shoulder 48. Although not shown in the FIGS., stria 46 also run horizontally and radially along the internal surface of shoulder 48 toward the longitudinal axis of upper container 14. When upper container 14 is disposed on lower container 12, stria 34 of edges 30 and 32 couple with stria 46 to
prevent upper container 14 and lower container 12 from rotating relative to each other.
As shown best in FIGS. 5-6, a plurality of sawteeth 50 are disposed on the external surface of shoulder 48. As shown in FIG. 7, sawteeth 50 mate with flexible wings 52 to removably couple safety seal 19 to upper container 14. Safety seal 19 has a ring-shaped geometry with a perforation at connecting point 58. Safety seal 19 has an axial wing 56
that is connected to the remainder of seal 19 at a connecting point 59. Upper container 14 also has a neck 55 having external threads 56 for mating with internal threads 60 of cap 18, as is best shown in FIG. 8. As is best shown in FIG. 5, upper container 14 has bottom 62 that is tearable along a perforated line 64 disposed about the periphery of bottom 62. Tubular sleeve 16 includes a hollow body 64 having a truncated cone-shaped portion 66 on one end and a helicoidal edge 68 on an opposite end. Truncated cone- shaped portion 66 has a internal channel 70 terminating in a reverse truncated cone- shaped hole 72 that serves as the nozzle or dropper to dispense a pharmaceutical
preparation from device 10. Alternatively truncated cone-shaped portion 66 may be modified to include a conventional "Luer Lok" that complies with Luer Taper Specification 70.1 of the American Standards Association and that allows coupling to a
syringe, cannula, or other conventional medical instruments. Helicoidal edge 68 preferably has a small horizontal section 74. Tubular sleeve 16 also includes a first sealing ring 76 and a second sealing ring 78 disposed on the external surface of body 64.
Sealing rings 76 and 78 mate with internal surface 84 of reservoir 20 of upper container
14 to prevent leakage of first component 22 from reservoir 20 or entry of air into reservoir
20. Sealing ring 78 is especially useful in preventing such leakage or entry when first component 22 is a liquid. As shown in FIG. 8, cap 18 preferably has a member 80 that seals hole 72 when cap 18 is screwed onto upper container 14.
The above-referenced description is a summary of the structure of device 10. Certain portions of device 10 are described in greater detail in U.S. Patent Nos. 5,474,209 and 5,782,345.
As mentioned hereinabove, reservoir 20 of upper container 14 holds first component 22 of a pharmaceutical preparation. Reservoir 24 of lower container 12 holds a second component 26 of a pharmaceutical preparation. Alternatively, first component
22 and second component 26 may be the unstable components of a liquid other than a pharmaceutical preparation.
First component 22 preferably comprises an ophthalmically effective amount of one or more pharmaceutically active agents. First component 22 may also comprise an ophthalmically acceptable carrier. As used herein, "ophthalmically acceptable carrier" refers to any substance or combination of substances that are non-reactive with the pharmaceutically active agent and suitable for administration to a user's eye. Solubilizers and stabilizers are deemed to be non-reactive. By way of example, an ophthalmically
acceptable carrier may comprise any combination of preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, solubilizers, stabilizers, pH adjusters, tonicity agents, fillers, and water. Preferred pharmaceutically active agents are agents for the prevention and/or treatment of cataracts. Preferred anti-cataract agents
include, without limitation, sodium pirenoxine. First component 22 may be in a powder
or liquid form.
Second component 26 preferably comprises an ophthalmically effective amount of
one or more pharmaceutically active agents. Second component 26 may also comprise an
ophthalmically acceptable carrier. Second component 26 preferably utilizes the same preferred pharmaceutically active agents as first component 22. Alternatively, second
component 26 may comprise an ophthalmically acceptable carrier but no pharmaceutically active agent. In this case, second component 26 acts as a diluent to first component 22. Still further in the alternative, first component 22 may comprise an ophthalmically acceptable carrier but no pharmaceutically active agent, and second component 26 may comprise one or more pharmaceutically active agents. In this case, first component 22 acts as a diluent for second component 26.
The above-described portions of device 10, including components 22 and 26 of a pharmaceutical preparation, are assembled using conventional techniques. Device 10 is preferably sterilized by conventional gamma radiation methods if such methods do not inhibit the efficacy of the pharmaceutical preparation. Alternatively, device 10 may be sterilized by conventional Eto methods, if necessary.
Referring generally to FIGS. 1-10, the preferred use of device 10 to mix components 22 and 26 of a pharmaceutical preparation and dispense the preparation into the eye of a user will now be described in greater detail. As shown in FIGS. 3-4, device 10 is in a first position in which components 22 and 26 are unmixed. To mix components 22 and 26, a user first moves axial wing 56 of safety seal 19 radially outward, breaking connecting point 59. The user then holds axial wing 56 and rotates safety seal 19 about a longitudinal axis of device 10, causing sawteeth 50 of upper container 14 to engage flexible wings 52 of safety seal 19. Such rotation splits safety seal 19 at connection point 58. The user can then remove safety seal 19 from device 10.
Next, the user screws cap 18 downward onto neck 55 of upper container 14.
During this downward travel of cap 18, internal shoulder 85 of cap 18 contacts external shoulder 86 of tubular sleeve 16. Tubular sleeve is pushed downward within upper
container 14 until external shoulder 86 of tubular sleeve 16 contacts shoulder 88 of upper container 14. Referring to FIG. 10, as tubular sleeve 16 is pushed downward, helicoidal edge 68 tears bottom 62 of reservoir 22 along perforation 64, with the exception of a
portion of perforation 64 at horizontal section 74 of edge 68. Bottom 62 is thus opened but remains connected to upper container 14. First component 22 is then in communication with second component 26, and may be further mixed by shaking device 10, if necessary. In this second position of device 10 in which components 22 and 26 are mixed, sealing rings 76 and 78 mate with internal surface 84 of upper container 14 to prevent leakage of the components from reservoirs 20 and 24 or entry of air into the reservoirs. Upon removal of cap 18, the mixed pharmaceutical preparation may be dispensed into the eye of a user by squeezing on the external surface of lower container 12 so as to force the mixture through nozzle 66 of tubular sleeve 16. When cap 18 is re- threaded onto tubular sleeve 16, member 80 seals hole 72.
The following example illustrates advantageous pharmaceutical preparations suitable for delivery with the device of the present invention, but are in no way limiting.
EXAMPLE Device 10 may be used to deliver an ophthalmic pharmaceutical preparation comprising a first component 22 that is a powder having sodium pirenoxine as a pharmaceutically active agent and a second component 26 that acts as a ophthalmically acceptable carrier for first component 22. First component 22 preferably has a weight of
75 mg and is formed using a conventional granulation process. First component 22 contains 0.714 % weight/weight sodium pirenoxine, 16.00 % weight/weight boric acid,
2.84 % weight/weight polyethylene glycol 6000, and a quantity of taurine sufficient to adjust the weight of first component 22 to 100%. The exact quantity of taurine may vary
slightly according to the potency of the sodium pirenoxine. 16.67 % volume/weight of
alcohol (96%) is also used during the granulation process used to form first component 22. The alcohol evaporates during the drying step of this process, before the filling of reservoir 20 with first component 22. Second component 26 preferably has a volume of
10 ml. The composition of second component 26 is 1.2 % weight/volume boric acid, 0.0095 % weight/volume sodium tetraborate 10 H2O, 0.16 % weight/volume potassium chloride, 0.02 % weight/volume nipagin M, 0.01 % weight/volume nipasol M, 0.1 % weight/volume thiomersal (0.1 % weight/volume solution), and a quantity of purified water sufficient to adjust the volume of second component 26 to 100%. When packaged as described hereinabove in device 10 as shown in FIG. 4, first component 22 and second component 26 exhibit good stability results for up to twenty-four months. When first component 22 and second component 26 are mixed in device 10 via the tearing of bottom 62 of reservoir 20, an effective anti-cataract pharmaceutical preparation may be delivered
to the eye.
The present invention is illustrated herein by example, and various modifications may be made by a person of ordinary skill in the art. For example, the geometries of the device and its individual components may be modified from the geometries described for the preferred embodiments. As another example, the device may be used with unstable ophthalmic pharmaceutically active agents other than anti-cataract agents, or with other
unstable liquids.
It is believed that the operation and construction of the present invention will be apparent from the foregoing description. While the apparatus, methods, and compositions
shown or described above have been characterized as being preferred, various changes and modifications may be made therein without departing from the spirit and scope of the
invention as defined in the following claims.
Claims
1. A device for the delivery of a pharmaceutical preparation to the eye having a first component and a second component, comprising:
an upper container for receiving said first component and having a bottom, said first component comprising an unstable anti-cataract agent; a lower container for receiving a second component, said second component comprising a liquid carrier for said first component; a tubular sleeve movably disposed within said upper container; and a cap rotationally coupled to said upper container; wherein when said cap is screwed onto said upper container, said tubular sleeve tears said bottom of said upper container to place said first component in communication with said second component.
2. The device of claim 1 wherein said first component comprises a liquid.
3. The device of claim 1 wherein said first component comprises a powder.
4. The device of claim 1 wherein said liquid carrier comprises a pharmaceutically active agent.
5. The device of claim 1 wherein said anti-cataract agent is sodium pirenoxine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17265799P | 1999-12-20 | 1999-12-20 | |
US60/172,657 | 1999-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001046035A1 true WO2001046035A1 (en) | 2001-06-28 |
Family
ID=22628636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/033925 WO2001046035A1 (en) | 1999-12-20 | 2000-12-15 | Container with two compartments and a mixing device |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001046035A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023667A1 (en) * | 2003-09-09 | 2005-03-17 | Aron Joseph Clarkson | Dispensing closure |
WO2009007828A1 (en) * | 2007-07-11 | 2009-01-15 | Ophthalmopharma Ag | Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins |
US8276748B2 (en) | 2007-03-16 | 2012-10-02 | The Coca-Cola Company | Ingredient release spout |
US8443969B2 (en) | 2007-03-16 | 2013-05-21 | The Coca-Cola Company | Ingredient release spout |
CN103211754A (en) * | 2012-01-19 | 2013-07-24 | 武汉诺安药业有限公司 | Production method of sterile stable pirenoxine sodium eye drops |
WO2016198967A1 (en) * | 2015-06-09 | 2016-12-15 | GONZÁLEZ SIERRA, Andres Fernando | Improved metering system |
USD960712S1 (en) * | 2018-10-29 | 2022-08-16 | Chubby Gorilla, Inc. | Dispenser |
US11498729B1 (en) | 2022-03-02 | 2022-11-15 | Jennifer Dianne Hugo | Dispenser |
US12024342B2 (en) | 2022-10-10 | 2024-07-02 | Jennifer Hugo | Dispenser |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577200A1 (en) * | 1992-07-02 | 1994-01-05 | Laboratorios Cusi, S.A. | Pharmaceutical product container for two separate substances, having a device for mixing and dosed dispensation |
EP0778221A1 (en) * | 1995-12-04 | 1997-06-11 | Laboratorios Cusi, S.A. | Pharmaceutical container with two seperate substances, with a mixing device, dosed application and assembly process thereof |
EP0885612A1 (en) * | 1997-06-06 | 1998-12-23 | Pharmaconsult s.a.s. | Pirenoxine for the topical treatment of inflammatory conditions |
-
2000
- 2000-12-15 WO PCT/US2000/033925 patent/WO2001046035A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577200A1 (en) * | 1992-07-02 | 1994-01-05 | Laboratorios Cusi, S.A. | Pharmaceutical product container for two separate substances, having a device for mixing and dosed dispensation |
EP0778221A1 (en) * | 1995-12-04 | 1997-06-11 | Laboratorios Cusi, S.A. | Pharmaceutical container with two seperate substances, with a mixing device, dosed application and assembly process thereof |
EP0885612A1 (en) * | 1997-06-06 | 1998-12-23 | Pharmaconsult s.a.s. | Pirenoxine for the topical treatment of inflammatory conditions |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1663807A1 (en) * | 2003-09-09 | 2006-06-07 | Aron Joseph Clarkson | Dispensing closure |
US7475774B2 (en) | 2003-09-09 | 2009-01-13 | Aron Joseph Clarkson | Dispensing closure |
WO2005023667A1 (en) * | 2003-09-09 | 2005-03-17 | Aron Joseph Clarkson | Dispensing closure |
EP1663807A4 (en) * | 2003-09-09 | 2009-01-21 | Aron Joseph Clarkson | Dispensing closure |
US8276748B2 (en) | 2007-03-16 | 2012-10-02 | The Coca-Cola Company | Ingredient release spout |
US8443969B2 (en) | 2007-03-16 | 2013-05-21 | The Coca-Cola Company | Ingredient release spout |
WO2009007828A1 (en) * | 2007-07-11 | 2009-01-15 | Ophthalmopharma Ag | Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins |
JP2010533221A (en) * | 2007-07-11 | 2010-10-21 | オフサルモファーマ・アクチェンゲゼルシャフト | Complex of prostaglandin derivative and monosubstituted charged beta cyclodextrin |
CN103211754A (en) * | 2012-01-19 | 2013-07-24 | 武汉诺安药业有限公司 | Production method of sterile stable pirenoxine sodium eye drops |
WO2016198967A1 (en) * | 2015-06-09 | 2016-12-15 | GONZÁLEZ SIERRA, Andres Fernando | Improved metering system |
US10301055B2 (en) | 2015-06-09 | 2019-05-28 | Andres Fernando Gonzalez Sierra | Dosing system |
USD960712S1 (en) * | 2018-10-29 | 2022-08-16 | Chubby Gorilla, Inc. | Dispenser |
US11498729B1 (en) | 2022-03-02 | 2022-11-15 | Jennifer Dianne Hugo | Dispenser |
US12024342B2 (en) | 2022-10-10 | 2024-07-02 | Jennifer Hugo | Dispenser |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020020636A1 (en) | Delivery of unstable pharmaceuticals | |
US7213593B2 (en) | Two-chamber cartridge for propellant-free metering aerosols | |
JP2602614B2 (en) | Chemical container | |
CA1240646A (en) | Mixing container and adapter | |
US4244467A (en) | Device for the extemporaneous preparation of a solution under sterile conditions | |
US4979941A (en) | Device suitable for mixing medication | |
JP2820249B2 (en) | Vial with resealable membrane assembly | |
US6572256B2 (en) | Multi-component, product handling and delivering system | |
RU2471474C2 (en) | Agent dispenser and sublingual device | |
US4346820A (en) | Apparatus for mixing and dispersing two substances under sterile conditions | |
JPH0611286B2 (en) | Medicine container and dispensing system | |
JPH0226506B2 (en) | ||
WO2014028745A2 (en) | A system for compounding and packaging ready to reconstitute drug powders of solutions to a solution or to a suspension or to an injectable | |
US20080125704A1 (en) | Liquid chamber cap with compartment for use with injectables | |
CA2248902A1 (en) | Improved mixing and delivery system | |
WO2000053241A2 (en) | Syringe device | |
WO2001046035A1 (en) | Container with two compartments and a mixing device | |
US20090263408A1 (en) | Formulation and presentation of medicaments | |
CA2065814A1 (en) | Dispenser device | |
JP2001502938A (en) | Syringe system containing two separate prefilled barrels | |
WO2003016170A1 (en) | Container plus syringe system | |
EP0483734A1 (en) | A device for the extemporary preparation and administration of solutions | |
JPH11319028A (en) | Eye drops |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): ES GE UA US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase |